
KMTS Stock Forecast & Price Target
KMTS Analyst Ratings
Bulls say
Kestra Medical Techs is poised for success with their innovative Cardiac Recovery System platform, including their ASSURE WCD, which has shown strong market demand and received FDA approval for a new algorithm. With a Buy rating and positive financial data, this company is well positioned for growth and collaborations with strategic partners only strengthen their potential. Despite potential risks, the positive outlook for Kestra Medical Techs suggests promising returns for investors.
Bears say
Kestra Medical Techs is facing commercial execution risks and potentially low physician adoption and prescription volumes, as well as potential hiccups in billing and collections processes. The company's profitability may be impacted by a higher than anticipated gross margin target and continued progress on prescription fulfillment and revenue cycle management. Additionally, the company may face challenges in expanding insurance coverage for their products, limiting their potential market reach.
This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
KMTS Analyst Forecast & Price Prediction
Start investing in KMTS
Order type
Buy in
Order amount
Est. shares
0 shares